Currently, it is a critical period for Shenzhen’s two-front battle to prevent and control the epidemic and resume work and production. On April 9, Dr. Hu Junyuan, chairman of Beike Biotech, was invited to be a guest on Shenzhen Radio and Television Pioneer 898’s “Resumption of Production and Work Pioneer Enterprises in Action” interview program to introduce how Beike Biotech contributed to the company’s own strength during the outbreak of the new coronavirus pneumonia.
The epidemic struck suddenly, and it was during the Spring Festival holiday. Beike Biotech responded immediately. On the second day of the new year, a meeting was held to establish an emergency response team for epidemic prevention and control, launch an epidemic contingency plan, and arrange relevant work from three aspects: deployment of prevention and control, employee health, and emergency supplies. Based on the characteristics of our business, During the entire Spring Festival holiday, our cell preparation, production and cell storage services will not stop, ensuring that technical services will not be suspended and service quality will not be compromised.
At the same time, the scientific research department of Beike Biotech responded immediately at the beginning of the epidemic. It cooperated with the Shenzhen Third People’s Hospital, the only designated hospital in Shenzhen to treat patients with new coronavirus pneumonia, and applied for the “Clinical Research on Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Severe Pneumonia Caused by Coronavirus” project, which was awarded Guangdong Provincial Department of Science and Technology’s 2020 Guangdong Provincial Emergency Response Project for New Coronavirus Prevention and Control (click to view).
During this epidemic, all walks of life are undergoing earth-shaking changes. The public’s awareness of personal health and family health has received unprecedented attention. After the epidemic, the health industry will also usher in huge changes.
And during the epidemic, we have seen that stem cells have made a great contribution in improving the treatment of (critical) patients with new coronary pneumonia, increasing the cure rate, and reducing the mortality rate. In the future, we may no longer need to rely on traditional drugs to treat diseases, but rely on cells and the body’s own repair ability to cure diseases. If healthy and viable cells can be stored 10 to 20 years in advance, there may be one more possibility in the future.
Beike Biotech has been committed to clinical translation research of personalized cell therapy, and at the beginning of this year, it won the highest honor award in the national science and technology community——“2019 National Technology Invention Award” (click to view) and assumed the Shenzhen Life and Health Industry Infrastructure——Shenzhen Comprehensive Cell BankConstruction and operation work. If you want to know more about the development trend of future medicine and knowledge about cells, Welcome toShenzhen Comprehensive Cell Bank Science Museum (click to view)Go visit.